The Physician Executive has his thoughts, but I think the reason is much simpler. Repackaging two cheap, generic medications into an expensive, brand-name pill is generally not a good business model for success.
Related posts:
- BiDil sales "suck"
- Racist not to cover BiDil?
- BiDil smoke and mirrors
- The Angry Pharmacist on the Medicare donut-hole
- Cutting back on prescription drugs
- Idiocy in Missouri
- The $130 million study that no one listened to
KevinMD.com on Facebook
Comments on this entry are closed.